BIO Web Conf.
Volume 61, 20236th International Conference on Frontiers of Biological Sciences and Engineering (FBSE 2023)
|Number of page(s)||18|
|Published online||21 June 2023|
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, China
* Corresponding author: firstname.lastname@example.org
Glucagon-like peptide-1 (GLP-1), an incretin secreted by intestinal L cells, has become a critical target for the treatment of type 2 diabetes because of its physiological effects of augmenting insulin secretion, suppressing glucagon secretion, and decelerating gastric emptying. Human endogenous GLP-1 is found to be proteolytically degraded and inactivated by DPP-4, which considerably limits the therapeutic effects of GLP-1. In contrast, GLP-1RAs undergo significant improvement in drug stability. In this context, several successful strategies for the development of GLP-1RAs and the corresponding problems are fully elaborated. The assay gives a brief overview of the pharmacological effects, advantages and common adverse effects of GLP-1RAs, shedding light on the latest research progress of GLP-1RAs, including new dosage forms, new drug targets and new clinical applications.
© The Authors, published by EDP Sciences, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.